A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
| Autor: | Coleman, Robert L., Sill, Michael W., Bell-McGuinn, Katherine, Aghajanian, Carol, Gray, Heidi J., Tewari, Krishnansu S., Rubin, Steven C., Rutherford, Thomas J., Chan, John K., Chen, Alice, Swisher, Elizabeth M. |
|---|---|
| Zdroj: | In Gynecologic Oncology June 2015 137(3):386-391 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect